Serious complications of chimeric antigen receptor T cell therapy / 中国小儿急救医学
Chinese Pediatric Emergency Medicine
;
(12): 589-594, 2022.
Artigo
em Chinês
| WPRIM
| ID: wpr-955101
ABSTRACT
Chimeric antigen receptor T cell (CAR-T) therapy is becoming the most promising treatment method in children and adolescent with refractory and relapse malignancies.While CAR-T cells exhibit powerful antitumour activity, this therapy has been associated with unique and significant toxicities including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) by triggering immune effector cells, even develop rapid and life-threatening cardiovascular, respiratory and/or neurological dysfunction.The assessment and grading of these adverse events vary widely in different clinical trials and institutions.For integrating the definitions and grading systems for toxicities from immune effector responses, in 2018, the American Bone Marrow Transplantation Society proposed consensus definitions and grading which is objective and easy to apply for CRS and ICANS.It helps clinicians and nurses make early critical care assessment and guide critical care interventions, thereby improving the efficacy and safety of CAR-T therapy.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Pediatric Emergency Medicine
Ano de publicação:
2022
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS